콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

SML1710

Sigma-Aldrich

Talniflumate

≥98% (HPLC)

동의어(들):

2-[[3-(Trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid 1,3-dihydro-3-oxo-1-isobenzofuranyl ester

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C21H13F3N2O4
CAS Number:
Molecular Weight:
414.33
UNSPSC 코드:
12352200
NACRES:
NA.77

Quality Level

분석

≥98% (HPLC)

양식

powder

색상

white to beige

solubility

DMSO: 5 mg/mL, clear (warmed)

저장 온도

room temp

SMILES string

FC(F)(F)c1cc(ccc1)Nc2ncccc2C(=O)OC3OC(=O)c4c3cccc4

InChI

1S/C21H13F3N2O4/c22-21(23,24)12-5-3-6-13(11-12)26-17-16(9-4-10-25-17)19(28)30-20-15-8-2-1-7-14(15)18(27)29-20/h1-11,20H,(H,25,26)

InChI key

ANMLJLFWUCQGKZ-UHFFFAOYSA-N

생화학적/생리학적 작용

Talniflumate is a phthalidyl ester of niflumic acid. It acts as an anti-inflammatory molecule and a mucoregulator. Talniflumate is used as a potent therapeutic for cystic fibrosis, chronic obstructive pulmonary disease and asthma. Talniflumate also inhibits the calcium-activated chloride channel hCLCA function, which is involved in mucus overproduction.
Talniflumate is an orally available, potent and selective inhibitor of core mucin-synthesizing enzyme GCNT3 (core 2 b-1,6 N-acetylglucosaminyltransferase). Talniflumate decreases GCNT3 expression and production of mucins in vivo and in vitro. Talniflumate improves responsiveness of pancreatic tumors to gefitinib. Talniflumate is a potent calcium-activated chloride channel (CaCC) blocker.
Talniflumate is an orally available, potent and selective inhibitor of core mucin-synthesizing enzyme GCNT3.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Talniflumate (Genaera).
Knight D.
Current Opinion in Investigational Drugs, 5(5), 557-562 (2004)
Nancy M Walker et al.
The Journal of pharmacology and experimental therapeutics, 317(1), 275-283 (2005-12-16)
Intestinal disease in cystic fibrosis (CF) mice closely mirrors aspects of obstructive syndromes in CF patients. The pathogenesis involves accumulation of mucoid debris in the crypts that fuse with intestinal content to form obstructing mucofeculant impactions. Treatment involves modalities that

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.